Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial

被引：5
|
作者：
Pieber, Thomas R. [1 ]
Bajaj, Harpreet S. [2 ]
Heller, Simon R. [3 ]
Jia, Ting [4 ]
Khunti, Kamlesh [5 ]
Klonoff, David C. [6 ]
Ladelund, Steen [4 ]
Leiter, Lawrence A. [7 ]
Wagner, Lily [4 ]
Philis-Tsimikas, Athena [8 ]
机构：
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Diabetol, Auenbruggerpl 2, A-8036 Graz, Austria
[2] LMC Diabet & Endocrinol, Brampton, ON, Canada
[3] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Mills Peninsula Med Ctr, Diabet Res Inst, San Mateo, CA USA
[7] Univ Toronto, St Michaels Hosp, Div Endocrinol & Metab, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[8] Scripps Whittier Diabet Inst, La Jolla, CA USA
来源：
DIABETES OBESITY & METABOLISM | 2022年 / 24卷 / 02期
关键词：
insulin analogues; insulin therapy; type; 2; diabetes; 300; U/ML; HYPOGLYCEMIA; VARIABILITY; THERAPY; DISEASE;
D O I：
10.1111/dom.14564
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 336
页数：5
相关论文
共 50 条
  • [1] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Athena Philis-Tsimikas
    David C. Klonoff
    Kamlesh Khunti
    Harpreet S. Bajaj
    Lawrence A. Leiter
    Melissa V. Hansen
    Lone N. Troelsen
    Steen Ladelund
    Simon Heller
    Thomas R. Pieber
    Diabetologia, 2020, 63 : 698 - 710
  • [2] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Philis-Tsimikas, Athena
    Klonoff, David C.
    Khunti, Kamlesh
    Bajaj, Harpreet S.
    Leiter, Lawrence A.
    Hansen, Melissa, V
    Troelsen, Lone N.
    Ladelund, Steen
    Heller, Simon
    Pieber, Thomas R.
    DIABETOLOGIA, 2020, 63 (04) : 698 - 710
  • [3] HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial
    Pieber, Thomas R.
    Bajaj, Harpreet S.
    Heller, Simon R.
    Jia, Ting
    Khunti, Kamlesh
    Klonoff, David C.
    Ladelund, Steen
    Leiter, Lawrence A.
    Hansen, Melissa V.
    Philis-Tsimikas, Athena
    DIABETES, 2020, 69
  • [4] HbA1c levels and rates of hypoglycaemia with insulin degludec U200 and insulin glargine U300 stratified by renal function subgroups: post hoc analysis from the CONCLUDE trial
    Heller, S. R.
    Pieber, T. R.
    Bajaj, H. S.
    Jia, T.
    Khunti, K.
    Klonoff, D. C.
    Ladelund, S.
    Leiter, L. A.
    Wagner, L.
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S319 - S319
  • [5] CONFIRM: a comparative effectiveness study of insulin degludec and insulin glargine 300 units/ ml (glargine U300) in insulin-naive patients with type 2 diabetes
    Tibaldi, J.
    Haldrup, S.
    Sandberg, V.
    Wolden, M. L.
    Rodbard, H. W.
    DIABETOLOGIA, 2018, 61 : S44 - S44
  • [6] Insulin glargine u300 versus insulin degludec around spontaneous exercise sessions in people with type 1 diabetes: the Ultraflexi-1 study
    Sourij, H.
    Mueller, A.
    Aberer, F.
    Aziz, F.
    Kojzar, H.
    Sourij, C.
    Obermayer, A.
    Abbas, F.
    Eckstein, M. L.
    Lenz, J.
    Sternad, C.
    Pferschy, P. N.
    Tripolt, N. J.
    Ziko, H.
    Moser, O.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S220 - S221
  • [7] Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison
    Yi Martin
    Tatsuya Zhou
    Yu-Shi Takagi
    International Journal of Clinical Pharmacy, 2022, 44 : 587 - 598
  • [8] Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison
    Martin
    Zhou, Yi
    Takagi, Tatsuya
    Tian, Yu-Shi
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (03) : 587 - 598
  • [9] Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study
    Chen, Liming
    Wan, Hailong
    Han, Jie
    Yang, Caixian
    Shao, Hailin
    Li, Jialin
    Yan, Wensheng
    Xiao, Jianzhong
    Sun, Yadong
    Li, Min
    Han, Yanfang
    Kang, Lei
    Zhang, Minlu
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1423 - 1431
  • [10] Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
    Evans, Marc
    Moes, Robert G. J.
    Pedersen, Katrine S.
    Gundgaard, Jens
    Pieber, Thomas R.
    ADVANCES IN THERAPY, 2020, 37 (05) : 2413 - 2426
12345